Narazaciclib, a novel multi-kinase inhibitor with potent activity against CSF1R, FLT3 and CDK6, shows strong anti-AML activity in defined preclinical models.

Autor: Yang, Tao1 (AUTHOR), Ke, Hang1 (AUTHOR), Liu, Jinping2 (AUTHOR), An, Xiaoyu2 (AUTHOR), Xue, Jia2 (AUTHOR), Ning, Jinying3 (AUTHOR), Hao, Feng3 (AUTHOR), Xiong, Lingxin2 (AUTHOR), Chen, Cen1 (AUTHOR), Wang, Yueying2 (AUTHOR), Zheng, Jia2 (AUTHOR), Gao, Bing2 (AUTHOR), Bao, Zhengzheng2 (AUTHOR), Gong, Kefeng2 (AUTHOR), Zhang, Lei1 (AUTHOR), Zhang, Faming1 (AUTHOR), Guo, Sheng2 (AUTHOR), Li, Qi-Xiang1 (AUTHOR) henry.li@hanxbio.com
Zdroj: Scientific Reports. 4/19/2024, Vol. 14 Issue 1, p1-13. 13p.
Databáze: Academic Search Ultimate
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje